← Leaderboards
Yangzom Doma Bhutia
Texas Tech University Health Scis Center
$1,196,289
Attributed
$1,196,289
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $355.1K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,196,289 · 2
By mechanism
R01$1,043,289 · 1
R03$153,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Texas Tech University Health Scis Center
Same institution · by research overlap
- Vadivel Ganapathy$5,868,327
- Jannette M Dufour$1,112,161
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsInnovationMalignant NeoplasmsTryptophanMonitorIn VitroInterestMalignant Neoplasm Of PancreasPancreatic Ductal AdenocarcinomaResponseCell LineDrug TargetingAmino Acid TransporterLaboratoriesAnti-CancerBiologicalBiochemicalExperimental StudyAutophagocytosisAttenuationAmino AcidsGeneticAttenuatedCarbon
Grant awards (5)
SLC6A14 as a unique drug target to treat pancreatic cancer$350,851
R01 · FY2025 · CA · contact PI
SLC6A14 as a unique drug target to treat pancreatic cancer$337,342
R01 · FY2024 · CA · contact PI
SLC6A14 as a unique drug target to treat pancreatic cancer$355,096
R01 · FY2023 · CA · contact PI
Carbidopa as an inhibitor of the TrpT/ID01 functional complex: A novel immunotherapy agent$76,500
R03 · FY2020 · CA · contact PI
Carbidopa as an inhibitor of the TrpT/ID01 functional complex: A novel immunotherapy agent$76,500
R03 · FY2019 · CA · contact PI